Pills, lozenges or tablets (A61K9/20)

Application of composition in medical products or drug manufacture for prevention and treatment of leukopenia caused by radiation and chemotherapy // 2642256
FIELD: pharmacology.SUBSTANCE: invention relates to application of a composition made from raw materials consisting of Radix Panacis Quinquefolii Ganoderma, or Radix Et Rhizoma Ginseng and fermented Cordyceps synesis powder and/or from Cordyceps, taken in a certain amount, in manufacture of medical products or drugs for prevention and treatment of radiation therapy or chemotherapy induced leukopenia in which the composition is obtained by raw materials mixing and extracting them with water and/or alcohol (versions).EFFECT: compositions described above are effective in the manufacture of medical products or drugs for prevention and treatment of radiotherapy or chemotherapy-induced leukopenia.25 cl, 36 tbl, 56 ex

Glp-1 peptides compositions and their production // 2641198
FIELD: pharmacology.SUBSTANCE: group of inventions concerns pharmaceutical compositions for treatment of diabetes or obesity, containing the first type of granules and the second type of granules, where the specified first type of granules contains the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and does not contain GLP-1 peptide, and where the specified second type of granules contains GLP-1 peptide and does not contain the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and also refers to methods for composition production and application in medicine.EFFECT: improving the bioavailability of the GLP-1 peptide.33 cl, 10 ex, 12 tbl

Oral film-forming basis and preparation // 2641092
FIELD: pharmacology.SUBSTANCE: oral film-forming basis consists of food polymer soluble in water and in organic solvent, with a solubility parameter equal to 9.7-20 (cal/cm3)1/2, a foam-forming means selected from sodium or ammonium hydrocarbons, or sodium, magnesium, ammonium, potassium or calcium carbonate, and an auxiliary foam-forming means foaming in the presence of water and selected from L-ascorbic acid, potassium L-bitartrate, calcium dihydropyrophosphate, disodium dihydropyrophosphate, galacturonic acid, glucuronic acid, monosodium fumarate, aluminium-potassium sulphate, sodium DL-malate, sodium dihydrophosphate, dipotassium hydrophosphate, sodium dihydrophosphate and disodium hydrophosphate, wherein both foam-forming and auxiliary foam-forming means are not soluble in the specified organic solvent and included in the form of particles with an average size of 0.1 to 60 microns, as well as to the drug, including the medicinal product in the specified basis and to methods for their production.EFFECT: group of inventions provides a rapid oral dissolution profile and sufficient film strength, reduced stickiness, improved absorption.17 cl, 47 ex, 13 tbl, 1 dwg

Gastroretentive dosage form and delivery systems and method of their production using functionalized calcium carbonate // 2640914
FIELD: pharmacology.SUBSTANCE: group of inventions refers to instantly floating gastroretentive finished dosage form, represented as a tablet, mini-tablet, granules, cap or pellets and containing a pharmaceutically active ingredient, formulating aid and functionalized natural and/or synthetic calcium carbonate, which has Brunauer-Emmett-Teller surface area of 5-200 m2/g and is a product of reaction of the natural or synthetic calcium carbonate with pharmaceutically acceptable acid and carbon dioxide, formed by acid treatment and/or supplied from an external source, where the source of the natural calcium carbonate is isolated from marble, calcite, chalk, limestone, dolomite and/or their mixtures. The synthetic calcium carbonate is precipitated calcium carbonate, containing an aragonitic, vaterite or calcitic mineralogic crystal forms. It also relates to the method of its production and application of the functionalized natural and/or synthetic calcium carbonate for its production.EFFECT: instantly floating properties of said finished dosage form and long stay in the stomach.31 cl, 4 dwg, 3 tbl, 1 ex
Peroral compositions containing ester 17- hydroxyprohesteron, and corresponding methods // 2640912
FIELD: pharmacology.SUBSTANCE: bioavailable peroral dosage forms are proposed, containing 17-hydroxyprohesteron caproate in the form of particles with an average diameter of 50 micron or less, as well as corresponding methods. Said peroral dosage forms can be prepared for pregnancy maintenance and contain a therapeutically effective amount of 17-hydroxyprohesteron caproate and pharmaceutically acceptable carrier. At least 20 wt % of 17-hydroxyprohesteron ester dose escape from said peroral dosage forms during determination using a device for dissolution of 2nd type in accordance with USP in 900 ml of deionised water with 0.5% (wt/vol) of sodium lauryl sulphate at 50 rpm and 37°C in 60 minutes.EFFECT: peroral form with high bioavailability.54 cl, 3 dwg, 54 ex, 14 tbl

Pharmaceutical composition and medicinal product based on clathrate complex of n-carbamoylmethyl-4-phenyl-2-pyrrolidone, or 4-phenylpyracetam with cyclodextrin, method for production (versions) // 2640081
FIELD: pharmacology.SUBSTANCE: group of inventions refers to a new clathrate complex of N-carbamoylmethyl-4-phenyl-2-pyrrolidone or 4-phenylpyracetam with cyclodextrin at a molar ratio of 1:1 to 1:10, respectively, and to versions of the method for its preparation, a composition comprising the said clathrate complex in an effective amount together with a pharmaceutically acceptable filler and/or excipient and a drug in the form of capsules, pills or an injection solution based on such a clathrate complex.EFFECT: preparation of stable complexes with high solubility in water.9 cl, 8 ex, 1 tbl, 7 dwg

Pharmaceutical combined drug // 2639818
FIELD: pharmacology.SUBSTANCE: invention relates to a drug for prevention or treatment of cardiovascular diseases comprising a granulated portion of fimsartan and a mixed portion of rosuvastatin, as well as meglumine.EFFECT: excellent effect in treatment of cardiovascular disease due to improved dissolution and dilution of the active substances, which provides better bioavailability and safety of the drug.19 cl, 5 ex, 3 tbl, 1 dwg

Pharmaceutical composition containing biotin and method for its production // 2639488
FIELD: pharmacology.SUBSTANCE: group of inventions refers to pharmaceutical compositions for polyneuropathy prevention and treatment as a solid dosage form with extended release, comprising Biotin - 40-60 wt % as an active agent, as well as Methocel K100 LV - 14-21 wt %, Methocel K4M - 5-10 wt %, microcrystalline cellulose (MCC) - 7-18 wt %, copovidone - 1.5-3 wt %, colloidal silicon dioxide - 0.4-1 wt % and a pharmaceutically acceptable stearic acid salt - 0.6-1 wt %, as well as to a method for its production, according to which Biotin, Methocel K4M, Methocel K100 LV, MCC and copovidone are sieved and mixed until homogeneous, stearic acid salt, colloidal silicon dioxide are mixed, the mixture is compacted by rolling, colloidal silicon dioxide is added and mixed together with pre-compacted grains, followed by addition of stearic acid salt, stirring and formation a solid dosage form.EFFECT: creation of a new medicinal composition with high technological properties, high stability and reproducible kinetics of active agent release.9 cl, 8 ex, 5 tbl, 1 dwg
Oral pharmaceutical composition // 2639473
FIELD: pharmacology.SUBSTANCE: invention represents a medicinal form of a non-coated pill containing α,α,α-trifluorothymidine and hydrochloride 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4(1N,3N)pyrimidinedione as active ingredients and, as such, not containing additives, including salt metals. The invention also includes a method for stabilization of an oral pharmaceutical composition containing the active ingredients described above.EFFECT: increased stability of the medicinal form.11 cl, 18 ex, 5 tbl
Solid oral pharmaceutical composition of s1p agonist or its pharmaceutically acceptable salt, method for its production and methods for treatment and reduction of frequency of clinical exacerbations of multiple sclerosis // 2639424
FIELD: pharmacology.SUBSTANCE: solid oral pharmaceutical composition consists of phignolimide hydrochloride in an amount of 0.4-0.65 mg, pregelatinized starch in an amount of 145-155 mg and magnesium stearate in an amount of 1.0-2.0 mg. The composition can be presented in the form of a pill or a capsule. The composition intended for treatment of relapsing-remitting multiple sclerosis, to reduce the frequency of clinical exacerbations of the disease and reduce the risk of disability progression in relapsing-remitting multiple sclerosis. The composition is administered orally in a dose of 500 μg, once a day.EFFECT: composition according to the invention is characterized by a high homogeneity of the active substance dosage, stability for prolonged storage and is capable of disintegrating and releasing the active substance rapidly during oral administration.5 cl, 10 tbl, 8 ex
Biotin tablets with delayed release and method for obtaining thereof // 2638803
FIELD: pharmacology.SUBSTANCE: invention is a pharmaceutical composition in the form of a pill that contains biotin as an active ingredient with a delayed release, and excipients, containing the following components, wt %: biotin 50-60, stabiliser 15-21, emulsifier 6-10, thickener 16.5-17, binder 1.5-3, debonder 0.4-1, lubricant 0.6-1.EFFECT: invention provides controlled release of the pharmaceutical composition of biotin in the presence of stable technological properties and stability.3 cl, 1 tbl, 5 ex
Combined drug for primary neuroprotection // 2636616
FIELD: pharmacology.SUBSTANCE: drug containing glycine and thiotriazoline is presented.EFFECT: high primary neuroprotective activity due to mutually reinforcing action, which are part of the preparations, and a wide range of biological effects.3 cl, 4 tbl
Composition containing alpha-lipoic acid and honokiol, for treatment of neuropathies // 2636613
FIELD: pharmacology.SUBSTANCE: invention relates to a composition comprising alpha-lipoic acid or a salt thereof and honokiol, wherein the amount of honokiol is 1% to 30% by weight based on the total weight of honokiol and alpha-lipoic acid. A pharmaceutical preparation and a dietary preparation for oral administration are also described. The preparations may be in the form of pills or capsules.EFFECT: drug is effective for treatment or prevention of peripheral neuropathies.17 cl, 2 dwg, 3 tbl, 3 ex
Chewing pill // 2634251
FIELD: pharmacology.SUBSTANCE: pill contains 1.5 g of beeswax, 1 g of medicinal herbs, including sage leaves, alfalfa grass, chamomile flowers, coltsfoot leaves, St. John's wort, yarrow, marigold flowers, oak bark, mint leaves, dandelion leaves, taken in an equal proportion, as well as 1 g of alginic acid per 1 pill.EFFECT: expanded spectrum of preventive and curative activity of the chewing pills.2 tbl
Pill containing methanesulfonate hydrate of 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2,3-dihydro-1h-isoindole-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid // 2633477
FIELD: pharmacology.SUBSTANCE: dosage form in the form of a pill according to this invention has a percentage of methanesulfonate hydrate of 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindole-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid from 80 wt % to 97.5 wt %.%. The pill has a size smaller than 200 mg of the commercially available Geninax pill.EFFECT: compliance with the drug regimen is improved, washability is high, crushing strength and abrasion resistance are high, the invention withstands film coating and transportation and is suitable as a methanesulfonic acid hydrate pill of chemical compound A.13 cl, 29 ex, 6 tbl

Solid dispersions produced by melt extrusion and containing apoptosis-inducing agent // 2633353
FIELD: pharmacology.SUBSTANCE: dispersion includes a compound of Formula I , where the value of R0, R1, R2, R3, R4, A, B, R5, X, Y and R6 groups is determined in the claims, or a pharmaceutically acceptable salt thereof. The compound of Formula I or its pharmaceutically acceptable salt are dispersed in a solid matrix which contains (a) at least one pharmaceutically acceptable water-soluble polymer carrier, and (b) at least one pharmaceutically acceptable surfactant. At least 5% of the compound of Formula I or its pharmaceutically acceptable salt is presented in the crystalline form, as studied by X-ray diffractometry. The compound or its pharmaceutically acceptable salt is presented in an amount equal to an amount of the parent compound from approximately 5% to approximately 40% by weight; at least one pharmaceutically acceptable water-soluble polymer carrier is presented in an amount from approximately 40% to approximately 85% by weight, and at least one pharmaceutically acceptable surfactant is presented in an amount from approximately 5% to approximately 20% by weight. A compound of Formula I in which R0 is chlorine, R1 and R2 are H, R3 and R4 are methyl, A is N, B is CH, R5 is nitro, X is -NH-, Y is - (CH2)n-, where n=1 , and R6 is selected from the group consisting of tetrahydropyranyl and 4-hydroxy-4-methylcyclohexyl, is excluded from the scope of the compound of Formula I. Methods for preparation of a solid dispersion suitable for oral delivery, a pharmaceutical dosage form and a solid dispersion for use as a medicament are also proposed.EFFECT: solid dispersion is applicable for oral administration to the patient in need of treatment of a disease characterised by overexpression of one or more Bcl-2 family antiapoptotic proteins.51 cl, 1 dwg, 17 tbl, 19 ex
Sedative and spasmolithic means and method for its production // 2633064
FIELD: pharmacology.SUBSTANCE: sedative and spasmolytic means containing phenobarbital, an oil component, auxiliary substances to create a solid dosage form that contains a dry or dense valerian extract containing 0.1 wt % and more of sesquiterpene acids in terms of valerenic acid, as an oil component, contains hop oil and peppermint oil or origanum oil and peppermint oil, taken in the ratio of 1:2-1:10, as auxiliary substances to create a solid dosage form in the form of pills or capsules contains: a filler, a binder, an aerosol, a disintegrant, an antifriction substance, with a certain ratio of said components. Method for production of a sedative and spasmolytic means.EFFECT: above-described sedative and spasmolytic means is characterized by reduced toxicity.6 cl, 5 tbl, 5 ex

Orally administrated adsorbent, therapeutic agent for kidney disease and therapeutic agent for liver disease // 2632432
FIELD: pharmacology.SUBSTANCE: orally administered adsorbent containing spherical activated carbon containing at least 0.5 wt % of nitrogen atoms which has a specific surface area determined by the Brunauer-Emmett-Teller method, from 700 to 3000 m2/g, and an average particle size of 0.01 to 1 mm. Therapeutic or prophylactic agent for kidney and kidney disease.EFFECT: high efficiency of method.7 cl, 4 dwg, 1 tbl, 35 ex
Water-dispersible desloratadine pill and method for its manufacture // 2631619
FIELD: pharmacology.SUBSTANCE: invention describes a pharmaceutical composition in the form of a dispersible pill comprising desloratadine and a method for its manufacture. A water-dispersible desloratadine pill is prepared by compressing the active ingredient in an amount of 2.5 or 5.0 mg with processing aids and pharmaceutically acceptable excipients and is capable of dispersing in water for 3 minutes to form a dispersion consisting of particles smaller than 710 mcm. The obtained pill possesses high stability and physical preservation, good mechanical properties in combination with fast disintegration in water solutions.EFFECT: experimentally selected composition allows for high processability of the dispersible pill manufacturing process.2 ex, 2 tbl

Adhesive material based on arabic gum, mixed with calcium carbonate, for oral adhesive discs // 2631485
FIELD: pharmacology.SUBSTANCE: invention relates to adhesive pastilles having two sides, so that if the pastille is in the mouth of a person, it adheres and stays in the mouth in the form of a single object that is not smeared and does not decay. These pastilles comprise the first disk-shaped layer with a flat side of at least 5 mm on two axes, containing an ingredient to be released into saliva; and the second adhesive disk-shaped layer with a flat side of at least 5 mm on two axes, containing at least 80% of arabic gum mixed with calcium carbonate at a ratio of calcium carbonate and arabic gum in the range of 1:15 to 1:50, so that the mixture pH is 5.5 or higher when dissolved in 10 parts of water. The first and the second layers are adhered to each other, side to side, so that the entire side of the resulting pastille is sticky, and all of its other side is not sticky. The invention also relates to a method for preparation of such pastilles.EFFECT: pastilles stability during storage, required pH value and sufficient strength of the adhesive layer.9 cl, 1 dwg, 3 tbl, 3 ex

Pharmaceutical composition // 2630617
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for treatment of cyclooxygenase-2 mediated diseases is described. The said composition includes, (2S)-7-tret-butyl-6-chloro-2- (trifluoromethyl)-2H-chromene-3-carboxylic acid as the active substance and a filler selected from tromethamine or meglumine. The filler is used in an amount of 0.5 wt % to 70 wt %. Two versions of the method for preparation of this composition and its application are also described.EFFECT: increased dissolution rate and oral bioavailability of the said composition, including the free form of the said compound.9 cl, 5 dwg, 16 tbl, 6 ex
ethod for chronic generalised periodontitis treatment // 2628806
FIELD: medicine.SUBSTANCE: pins containing propolis, herbs and alginic acid, with the following components content, g per 1 pin: propolis 1; herbs 1; alginic acid 1, is injected into the periodontal pockets for 15 minutes during 5 days. Then, applications of gum plates containing propolis, collection of medicinal herbs and alginic acid with the following components content, g per plate: propolis 1.5; collection of herbs 1; alginic acid 1 are performed for 20 minutes. Chewable tablets containing beeswax, collection of medicinal herbs and alginic acid with the following components content, g per 1 tablet: beeswax 1.5; collection of herbs 1; alginic acid 1, are prescribed for taking in between meals.EFFECT: effective treatment of chronic generalized periodontitis with shortening of treatment terms.1 tbl, 2 ex

Composition including amlodipine and losartan having improved stability // 2628538
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for cardiovascular disorders prevention and treatment is described. The said composition comprises amlodipine besylate in an amount of 1.7 to 1.72 wt %, potassium losartan in an amount of 12.22 to 12.37 wt %, and propyl gallate in an amount of 0.01 wt %, based on the total weight of the composition. The said composition has the form of a two-layer pill having two separate layers consisting of an amlodipine layer containing amlodipine besylate and propyl gallate and a layer of losartan containing potassium losartan.EFFECT: improved composition stability in combination with simplicity of preparation.6 cl, 21 tbl, 2 dwg, 5 ex

ethod of production of a combined antihelmint tablet with a symbiotic treatment for treatment of a small cattle // 2627893
FIELD: veterinary medicine.SUBSTANCE: invention is a method for producing a combined anthelmintic tablet with a symbiotic for treating small cattle containing a first and second layer comprising the steps of: adding a first powder mixture to a mould plate. Mentioned first powder mixture contains a pharmaceutically active substance and a binder, a second powder mixture is added to said mould plate. Mentioned second powder blend comprises a binder and the composition of mentioned second powder blend is different from the composition of mentioned first powder mixture, the first powder mixture and the second powder blend are pressed on said plate of the mould to form a tablet form and subjected to said tableted form with radio frequency emission for a period of Time sufficient to activate said binder within said tablet mould to fuse mentioned tableted Th form into said tablet, such that the density of mentioned tablet is less than about 0.8 g/cm3, characterized in that a bacterial concentrate is prepared for the preparation of the first powder mixture comprising a bifidobacterium adolescentis B-1 and Lactobacillus acidophilus LH-1 consortium with a titre of 108-1010 CFU/g sorbed on a carrier in a ratio of 1:1:12, which Is concentrated by filtration or centrifugation to a suspension containing 5 billion bacteria per ml, followed by mixing them in equal volumes. As the carrier, flour or bran is used at the rate of 12 parts of the support per part of a mixture of concentrated cultures, and then the obtained dry powder mass is mixed with lactulose, and to obtain the second powder mixture, ivermectin, praziquantel and at least one pharmaceutically acceptable excipient microcrystalline cellulose MCC is used, then the substances ivermectin, praziquantel and excipient are mixed in dry kind. The components in the tablet are in a certain ratio in wt %.EFFECT: invention provides high anthelmintic activity, intensification of treatment and prevention of a number of helminthic invasions, nonspecific correction of the immune response of the animal organism, normalization of hepatoprotective and reparative liver functions.6 ex, 1 tbl, 1 dwg

Preparations of {2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl} amide of cyclopropanecarboxylic acid // 2627471
FIELD: pharmacology.SUBSTANCE: invention relates to an oral dosage form comprising an amorphous dispersion of {2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} amide of cyclopropanecarboxylic acid or a pharmaceutically acceptable salt thereof in a hydrophilic polymer, wherein the hydrophilic polymer is hydroxypropylmethylcellulose. Also, methods for treatment, control or prevention of various diseases such as cancer or inflammatory disease are proposed.EFFECT: creation of a dosage form with rapid disintegration, reduced friability, content uniformity, rheological properties required for production, solubility, bioavailability, stability and desired hardness.9 cl, 4 dwg, 2 tbl, 1 ex
Starch-free soft chewing gums // 2627420
FIELD: pharmacology.SUBSTANCE: group of inventions refers to a soft chewing gum, which comprises: (a) a pharmaceutically effective amount of at least one active ingredient; (b) a flavoring agent of animal origin; (c) at least 10 wt % of a disintegrating agent in the final composition, which is selected from the group consisting of i) carmellose calcium, ii) directly compressible mannitol, and iii) a mixture or combination of croscarmellose sodium and directly compressible mannitol; (d) at least 10 wt % of a wetting agent in the final composition; (e) a binding agent; (f) an antioxidant; (g) optionally, a preservative; and (h) water; where the soft chewing gum contains less than about 2 wt % of each of polyethylene glycol (PEG), propylene glycol, starch, soy products and wax. Also, the group of inventions refers to a method for the said soft chewing gum production.EFFECT: short time of soft chewing gum decomposition, retained even after prolonged storage at elevated temperature.11 cl, 1 ex, 4 tbl, 3 dwg
Tablet comprising dehydroepiandrosterone (dhea) // 2627111
FIELD: pharmacology.SUBSTANCE: group of inventions relates to tablet for preventing the loss of testosterone, for maintaining physiological levels of androgens, improving sexual function, mood and health, having a weight of 60-120 mg and consisting of: - 60-100 wt % of granules consisting of: 60-85 wt % of dehydroepiandrosterone (DHEA) granules; 6-35 wt % of microcrystalline cellulose granules; 0-20 wt % of granules of one or more pharmaceutically acceptable granule ingredients; and - 0-40 wt % of one or more pharmaceutically acceptable tablet components, as well as to method of preparing the mentioned tablets.EFFECT: preparation of small tablets with a high content of DHEA, having acceptable release profile.18 cl, 10 ex
Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophene-5-yl)etoxy)propyl)azetidine-3-ol or its salt // 2625767
FIELD: pharmacology.SUBSTANCE: solid pharmaceutical formulation as a pill, comprising 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)azetidine-3-ol or a salt thereof in an amount of 30% to 90% The said pill also contains a component selected from mannitol, sorbitol and isomaltose in an amount of 6% to 60% by weight, and a disintegrant selected from the group consisting of cellulose derivatives, starch derivatives and polypyrrolidone derivatives in an amount of 3% to 10% by weight.EFFECT: invention provides excellent solubility, hardness for dosage forms and increased stability in long-term storage.11 cl, 15 ex, 5 tbl
Pharmacological composition on basis of iron compounds // 2625739
FIELD: pharmacology.SUBSTANCE: invention is a pharmacological composition containing the iron (II) sulphate for treatment of iron deficiency anemia, characterised in that it additionally contains iron hexacyanoferrate, iron-potassium hexacyanoferrate, potassium sulfate and micro cellulose, the components in the composition being in a certain ratio, in weight percent.EFFECT: high therapeutic efficacy, good tolerability, and low toxicity.2 cl, 5 ex

Pharmaceutical composition with anti-therapeutic activity and method of its production // 2624857
FIELD: pharmacology.SUBSTANCE: composition contains 2-[(1Z)-1-(3,5-diphenyl-1,3,4-thiadiazol-2(3H)-ylidene chloride)methyl]-3,5-diphenyl-1,3,4-tiadiazol-3-th (TDZ) in an amount of 15 to 50 wt %, Polyethylene oxide, in an amount of 15 to 50 wt %, Poloxamer, in an amount of 5 to 20 wt % Lecithin, in an amount of 1 to 5 wt %, and pharmaceutically acceptable excipients. According to the process for preparing the composition, the TPD is dissolved in ethyl or isopropyl alcohol, methylene chloride or mixtures thereof, polyethylene oxide, poloxamer and lecithin are introduced into the solution, then other pharmaceutically acceptable excipients are added to the mixture, the mixture is dried, granulated, and tablets or capsules are prepared.EFFECT: inventions allow to increase the release of the active substance from the tablet or granules and to improve the antifungal activity of the substance.6 cl, 1 dwg, 3 tbl, 6 ex

Pharmaceutical composition containing tetrahydropholic acid // 2624236
FIELD: pharmacology.SUBSTANCE: oral dosage form comprises progestogen, estrogen, 5-methyl-(6S)-tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient or carrier, and comprises granulating of progestogen and estrogen and at least one pharmaceutically acceptable excipient in the fluidized bed, mixing of 5-methyl-(6S)-tetrahydrofolic acid or the pharmaceutically acceptable salt thereof with granules, and further granulation by maintaining the fluidized bed and formation of a solid oral dosage form from granules.EFFECT: compositions of the invention provide good stability of tetrahydrofolic acid during storage and at the same time provide a rapid release of estrogen and progestogen present in the composition.14 cl, 3 dwg, 5 tbl, 6 ex
Pharmaceutical composition containing memantine and melatonin combination // 2623865
FIELD: pharmacology.SUBSTANCE: invention is a pharmaceutical composition in the form of a pille dispersed in the mouth, containing: 2.0 to 15.0 wt % of memantine; 1.0 to 10.0 wt % of melatonin; 65.0 to 80.0 wt % of the filler selected from mannitol or mannitol mixture with copovidone; 4.0 to 15.0 wt % of desintegrant, selected from crospovidone; 1.0 to 2.0 wt % of the binding substance, selected from sorbitol; 1.0 to 2.5 wt % of the sweetener selected from maltitol, sodium saccharinate, or a mixture thereof; 0.5 to 1.0 wt % of the sliding substance selected from colloidal silicon dioxide, stearic acid, magnesium stearate, talc or mixtures thereof; 1.5 to 3.0 wt % of flavor, as well as a production method.EFFECT: expansion of the arsenal of pharmaceutical compositions containing a combination of memantine and melatonin, increased storage stability and dissolution rate.12 cl, 6 ex
Pharmaceutical composition for sleep disorders prevention and treatment // 2620855
FIELD: pharmacology.SUBSTANCE: invention relates to a pharmaceutical composition for sleep initiating and maintaining and prophylaxis of animal and human states that are accompanied by sleep disorders of a different nature, including a combination of active agents consisting of 0.5-45 mg of doxylamine succinate and long-acting melatonin in amount of 0.1-20 mg.EFFECT: synergistic therapeutic effect and reduced side effects.2 cl, 1 tbl, 5 ex
Composition containing paracetamol and glutathione, and method for its obtaining // 2620340
FIELD: pharmacology.SUBSTANCE: analgesic composition for oral administration is proposed, comprising from 1 to 15 wt % of reduced glutathione, and from 5 to 45 wt % of paracetamol as active agents. The composition described in the present invention can be used for preparing various medicinal forms in accordance with conventional methods of formulating, such as tablets, slow acting agents/agents with controlled release, capsules, pills, syrups, film-forming agents, granules, oral solutions, oral suspensions, emulsions, oral powders, and any other pharmaceutically acceptable medicinal forms.EFFECT: compositions described in the present invention can not only effectively prevent the damage and necrosis of liver cells caused by paracetamol overdose, but also provide a good effect of treating pain in cancer and chemotherapy.7 cl, 3 ex
Implantable naltrexone tablets // 2620254
FIELD: medicine.SUBSTANCE: implantable naltrexone tablets and method for sterilizing implantable naltrexone tablets are described. The implantable tablet comprises naltrexone in an amount of 500-2000 mg placed in a cavity formed by moulded biodegradable polymer based on DL-lactides and/or DL-glycolides, adding Eudragit pharmaceutical polymer and a lubricant to provide controlled release of the active substance for 3 months or more. The lubricant consists of stearic acid or glyceryl monostearate to prevent tissue irritation and inflammation at the implantation site.EFFECT: implantable naltrexone tablets, free of magnesium stearate and triamcinolone, are obtained, in order not only to reduce the metabolic load on the liver, but also reduce toxicity and carcinogenicity.7 cl, 2 tbl, 6 ex
Solid pharmaceutical form of immediately releasing zafirlukast and method of its production // 2619213
FIELD: pharmacology.SUBSTANCE: invention relates to a solid pharmaceutical form of zafirlukast having anti-inflammatory, anti-asthmatic, bronchospasm-warning action, which is a coated tablet containing zafirlukast and target additives at the following component ratio, %: core: zafirlukast - 7.8-10.2, calcium hydrophosphate dihydrate - 25.0-35.0, Prosolve - 22.0-40.0, hypromellose - 3.0-8.0, pregelatinized starch - 10.2-25.5, croscarmellose sodium - 1.0-3.0, aerosil - 0.5-3.0, stearic acid and/or its salts - 0.5-1.0; shell: hypromellose - 0.5-1.4, titanium dioxide - 0.3-0.6, macrogol - 0.1-0.6. The invention also relates to a process for preparation of a solid form of zafirlukast which includes a direct compression method.EFFECT: invention allows to obtain solid forms of zafirlukast, in particular in the form of pills, characterized by good disintegration and strength, as well as rapid solubility.10 cl, 3 tbl
Combined preparation of lercanidipine and atorvastatin // 2617048
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and pharmacy. Combined preparation of lercanidipine hydrochloride and calcium atorvastatin is disclosed for treating hypertension accompanied by hyperlipidemia, which contains single dose of 5–20 mg of lercanidipine hydrochloride and 10–80 mg of atorvastatin calcium, wherein weight ratio of lercanidipine hydrochloride to atorvastatin calcium is 1:2–4, and method of producing coated tablet containing them.EFFECT: technical result is combined preparation of lercanidipine and calcium atorvastatin according to this invention has higher efficiency at lower dose as compared to combined introduction of tablets with respect to considerable reduction of hypertension and reducing level of lipids; it is characterized by low therapeutic dose and reduction of number of undesired effects, as well as good tolerance and compliance with drug therapy regimen of patients.8 cl, 7 tbl

ethod of medicinal herb tabletting // 2616905
FIELD: pharmacology.SUBSTANCE: method of medicinal herb tabletting comprising grinding of the medicinal herb, drying and tabletting, wherein the flows of sprayed ground medicinal herb and sprayed solution of starch dextrins are mixed, thereby covering particles of the medicinal herb with starch dextrins film, the medicinal herb is dried in starch dextrins, the dried material in starch dextrins is splashed with water vapour before tabletting.EFFECT: method enables to reduce the loss of herbal raw material active agents, facilitates rapid disintegration in the gastrointestinal tract.2 dwg
Liquid lubricant for tableting, integrated into tablets // 2615823
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical and nutriceutical tablets. Method of producing tablets includes provision of matrix with liquid lubricant included in its composition, containing oily fluid finely dispersed in oil-insoluble material, provision of composition of food additive or pharmaceutically active composition, mixing of matrix with liquid lubricant included in its composition and composition of food additive or pharmaceutically active composition and formation of tablet. Wherein matrix with liquid lubricant included in its composition ranges from 0.3 % to 8.8 % of tablet, and composition of food additive or pharmaceutically active composition contains no stearate.EFFECT: invention allows to improve lubrication of dry nutraceutical and/or pharmaceutical compositions for tabletting.21 cl, 2 tbl, 3 ex

Antibacterial agents and method for treating intestinal yersiniosis or pseudotuberculosis, or colibacillosis // 2614730
FIELD: pharmacology.SUBSTANCE: antibacterial agent comprises a calcium lactate in the effective therapeutic dose. The treatment method comprises the enterally introduced antibacterial agents.EFFECT: increasing the therapeutic agent and method activity by increasing the intestinal colonization resistance, eliminating dysbiosis and preventing morphofuctional disorders of the intestinal mucosa.7 cl, 1 dwg, 2 tbl

Pharmaceutical composition for oral administration containing statin // 2614728
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical composition for oral administration containing or consisting of: (i) from 11 to 25 wt% of simvastatin, (ii) from 0.01 to 3 % by weight of first substance (A1) with antioxidant activity, which is butylhydroxyanisole, (iii) from 0.01 to 3 % by weight of second substance (A2) with antioxidant activity, differing from first substance (A1) with antioxidant activity, which is citric acid, and (iv) from 75 to 85 wt% of at least one additive selected from group consisting of filler, binder, agents for controlling fluidity, baking powder and agent preventing adhesion or combinations thereof, where quantitative ratio of butylhydroxyanisole (A1) and citric acid (A2) ranges from 1:95 to 1:30, and wherein above composition is compacted in form of tablet and said tablet has mass from 130 to 300 mg.EFFECT: invention also relates to use of said pharmaceutical composition in medicine.12 cl, 2 ex, 4 tbl, 5 dwg
Pharmaceutical composition comprising fimasartan and hydrochlorothiazide // 2613900
FIELD: medicine, pharmacy.SUBSTANCE: pharmaceutical composition comprises 132.02 mg of potassium fimasartan trihydrate, 12.5 mg of hydrochlorothiazide and a binder, which binding solution has a viscosity from 20 mPa·s to 650 mPa·s. The binder includes at least one substance selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose and polyvinylpyrrolidone. A method for preparation of a pharmaceutical composition by wet granulation and a pill obtained in this manner are also described. This composition is characterized by a standard deviation (RSD) of 4.0% or less in the content uniformity test of the active ingredients. The uncoated pill has a crush strength of 7 Kp or more as per the invention.EFFECT: invention refers to a pharmaceutical composition in the form of pill for hypertension treatment.9 cl, 12 tbl, 11 ex
Biologically active composition in form of lozenge // 2613180
FIELD: biotechnology.SUBSTANCE: biologically active composition in the form suitable for oral resorption, contains L-theanine or diosgenin or a dry extract of Dioscorea villosa (wild yam) rhizomes containing these substances in effective amounts, and auxiliaries. The lozenges provide higher diosgenin bioavailability.EFFECT: improved condition in case of physical fatigue of various origins.2 cl, 4 ex
Solid preparations containing pelargonium sidoides extracts and silicic acid compounds and production methods // 2612085
FIELD: pharmacy.SUBSTANCE: solid preparation for respiratory diseases treatment, containing a Pelargonium sidoides extract and calcium silicate in a specific weight ratio. A method for solid preparation production for respiratory diseases treatment.EFFECT: increased hardness and reduced abrasion.6 cl, 4 tbl
Dispersible in water acetylcysteine tablet and method of manufacturing thereof // 2611411
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of pharmaceutics. Described is dispersible in water acetylcysteine tablet, which contains from 100 to 600 mg of said substance and auxiliary components, taken in ratio 1:1 to the total weight from 200 to 1200 mg. Active and auxiliary substances are used in the following weight ratio, %: acetylcysteine - 50.0; microcrystalline cellulose - 34.1; lactose monohydrate - 5.0; crospovidone - 5.0; povidone - 25-2.0; lemon flavour - 1.0; sodium saccharinate - 0.825; aspartame - 0.675; citric acid monohydrate - 0.325; colloidal silicon dioxide - 0.75; magnesium stearate - 0.75. Tablet is capable of dispersing in water at temperature 15-25°C within 3 minutes with formation of dispersion, consisting of particles with size smaller than 710 mcm.EFFECT: obtained tablet possesses high stability and physical preservation, good mechanical properties in combination with fast disintegration in water solutions.2 cl, 3 ex, 4 tbl
Drug based on tetrametiltetraazobitsiklooktandion and method for its production // 2611194
FIELD: pharmacy.SUBSTANCE: here is a description of dosage form of tetrametiltetraazobitsiklooktandion, additionally containing a filler, granulating agent, lubricant, disintegrant, flavoring agent in certain weight ratios. Methods of preparing of the said dosage form are also described.EFFECT: preparation of the dosage form without defects in manufacture and storage and with improved taste characteristics.11 cl, 3 tbl
Anti-inflammatory composition with prolonged action for treating airway // 2608126
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and concerns anti-inflammatory composition for treating upper airways. Anti-inflammatory composition for treating upper airway in form of tablets containing echinacea dry extract, evkalimine, colloidal silicon dioxide, sodium stearyl fumarate, dextrose monohydrate, taken in certain amount.EFFECT: composition described above, in form of tablets, has high pharmaceutical activity with respect to treating upper airways, it is stable during storage.1 cl, 1 tbl, 2 ex

Destruction-resistant dosage form containing anionic polymer // 2607499
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics, namely to dosage form in form of tablets with tensile strength of at least 500 N containing pharmacologically active component (A) selected from hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, tramadol and their pharmaceutically acceptable salts; polymer (B) selected from (i) homopolymer of acrylic acid, cross-linked allyl sucrose or allyl pentaerythritol, or (ii) copolymer of acrylic acid and C10-C30-alkyl-acrylate, cross-linked allyl pentaerythritol, or (iii) interpolymer selected from homopolymers of acrylic acid, cross-linked allyl sucrose or allyl pentaerythritol, and copolymers of acrylic acid and C10-C30-alkyl-acrylate, cross-linked allyl pentaerythritol containing copolymer block of polyethylene glycol and ester of C8-C30-alkyl acid; and from 30 to 90 wt% of polyethylene oxide (C) with average molecular weight from 2,500,000 to 15,000,000 g/mol, wherein component (A) is present in controlled-release matrix containing polymer (B) and polyethylene oxide (C).EFFECT: invention provides production of destruction-resistant dosage forms with prolonged release of active component.5 cl, 8 ex, 19 tbl, 16 dwg
Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs // 2606845
FIELD: pharmaceutics.SUBSTANCE: group of inventions refers to medicine and pharmacology, and can be used for preparing solid pharmaceutical composition, wherein the solid pharmaceutical composition contains: (i) amorphous solid solution of 9-[2-[bis[(pivaloiloxy)-methoxy]phosphinyl]methoxy]ethyl]adenine (AD) and a copolymer of vinylpyrrolidone and vinyl acetate and (ii) one or more pharmaceutically acceptable inactive ingredients selected from microcrystalline cellulose, silicon dioxide and magnesium stearate, wherein the solid pharmaceutical composition is stable, such that when the solid pharmaceutical composition is stored at 40 °C and relative humidity of 75 % in a closed container for 3 months, amount of impurities presented in the solid pharmaceutical composition, is not more than 0.74 weight. % in relation to the initial number of AD, wherein the admixture is 9-[2-(pivaloiloxy)-methoxyphosphinyl]methoxy]ethyl]adenine; at that, the method comprises the following steps: (i) producing amorphous solid solution of AD and copolymer of vinylpyrrolidone and vinyl acetate by dissolving the initial quantity of AD and copolymer of vinylpyrrolidone and vinyl acetate in a volatile organic solvent selected from ketones and halocarbons, evaporation of the volatile organic solvent and (ii) dry mixing of the obtained amorphous solid solution with one or more pharmaceutically acceptable inactive ingredients. Solid pharmaceutical composition and packing system are also disclosed.EFFECT: group of inventions ensures production of highly-stable composition having storage stability.10 cl, 5 tbl, 3 ex
Pharmaceutical composition containing rosuvastatin calcium salt (versions) // 2606592
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and medicine, namely to production of medicinal preparations for treating hypercholesteremia, atherosclerosis, lipid storage disease. 4 versions of pharmaceutical composition are proposed. According to 2 versions pharmaceutical composition contains calcium rosuvastatin in amount of 5 mg or 10, 20 or 40 mg and as auxiliary substances it has microcrystalline cellulose, mannitol, calcium dihydrophosphate, corn starch, talc, magnesium stearate. According to other 2 versions pharmaceutical composition contains calcium rosuvastatin in amount of 5 mg or 10, 20 or 40 mg and as auxiliary substances it has microcrystalline cellulose, mannitol, crospovidone, talc, magnesium stearate. Pharmaceutical composition is presented in form of tablet, film-coated, or in form of capsules.EFFECT: invention widens range of drugs for treating lipid storage disease, atherosclerosis, hypercholesterinemia.20 cl, 14 tbl
 
2551050.
Up!